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most of them were compound heterozygote (76.2%). p.Val377Ile was
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Abstract: The aim of this study was to describe the clinical and
biological features of Mevalonate kinase deficiency (MKD) in patients
diagnosed in adulthood.
This is a French and Belgian observational retrospective study from
2000 to 2014. To constitute the cohort, we cross-check the genetic and
biochemical databases. The clinical, enzymatic, and genetic data were
gathered from medical records.
Twenty-three patients were analyzed. The mean age at diagnosis
was 40 years, with a mean age at onset of symptoms of 3 years. All
symptomatic patients had fever. Febrile attacks weremostly associated
with arthralgia (90.9%); lymphadenopathy, abdominal pain, and skin
lesions (86.4%); pharyngitis (63.6%); cough (59.1%); diarrhea, and
hepatosplenomegaly (50.0%). Seven patients had psychiatric symp-
toms (31.8%). One patient developed recurrent seizures. Three patients
experienced renal involvement (13.6%). Two patients had angiomyo-udia, MD, Delphin lch, MD, PhD,
Arnaud Hot, MD, PhD
themost prevalent mutation. Structural articular damages and systemic
AA amyloidosiswere the 2most serious complications.More than 65%
of patients displayed decrease in severity and frequency of attacks with
increasing age, but only 35% achieved remission.
MKD diagnosed in adulthood shared clinical and genetic features
with classical pediatric disease. An elevated IgD concentration is a
good marker for MKD in adults. Despite a decrease of severity and
frequency of attacks with age, only one-third of patients achieved
spontaneous remission.
(Medicine 95(11):e3027)
Abbreviations: CRP = C-reactive protein, ENT = ear-nose-throat,
HIDS = Hyperimmunoglobulinemia D and periodic feverunoglobulin, IL = Interleukin, MA =
MK = mevalonate kinase, MKD =
ciency.
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TABLE 1. Demographic Data
Age at time of diagnosis in years,
median/mean (range)
37/40 (16–79)
Age at onset of symptoms in years,
median/mean (range)
3/9 (0.2–77)
Age repartition at onset of symptoms, n (%)
6 months 6 (27.3)
6 months–5 years 7 (31.8)
5–10 years 5 (22.7)
>10 years 4 (18.2)
Sex (male/female) (n) 9/14
Medicine  Volume 95, Number 11, March 2016INTRODUCTION
M evalonate kinase deficiency (MKD) is a rare autoinflam-matory autosomal recessive periodic fever disorder.1,2
Hyperimmunoglobulinemia D and periodic fever syndrome
(HIDS) and mevalonic aciduria (MA) are both part of the
MKD spectrum.3,4 They result from mutations in the gene
encoding mevalonate kinase (MK). This is a key enzyme in
cholesterol and non-sterol isoprenoids biosynthesis, which are
important compounds in a lot of vital cellular functions. A
deficient MK activity leads to shortage of isoprenoids down-
stream compounds and systemic inflammation through inter-
leukin (IL)-1b-mediation.5 HIDS and MA are the 2 extreme
phenotypes of a continuous spectrum with a mild and severe
form, respectively, correlated with the residual MK activity.6–9
In fact, there must be apparently healthy people to stillbirth.10
The patients suffered from lifelong febrile attacks that last 3 to 7
days and recur every 4 to 6 weeks with varying associated
combination symptoms, such as painful lymphadenopathy,
abdominal pain, arthralgia or arthritis, diarrhea and vomiting,
skin lesions, headache, cold chills, aphtous ulcers, and hepa-
tosplenomegaly.11 MA patients had also dysmorphic features,
growth retardation, and neurological involvement.
HIDS is the historical name of the pathology and owes its
name to the increase of immunoglobulin (Ig) D serum level
reported in the first description.7 Nevertheless, elevated IgD
remains an inconsistent finding.12,13
Despite a mean diagnostic delay >10 years, first HIDS
attacks usually occur in early childhood.12,14 Exceptional
worldwide cases of adult-onset MKD without previous feverish
history have been reported but poorly described.14 We conduct
this study to assess the clinical and biological conditions of a
multicenter cohort of patients diagnosed with MKD in adult-
hood. We describe the spectrum of clinical and biological
phenotype, and genotype at diagnosis. The long-term compli-
cations of the spontaneous course of the disease are noted.
METHOD
Patients were identified on genetic analysis, or enzymati-
cally proven with a family history of MKD or typical clinical
features, in France and Belgian. This was a retrospective study
from January 2000 (after the availability of the genetic assay) to
December 2014.3 To constitute an exhaustive cohort, we cross-
checked the database of the 2 French competent genetic labora-
tories in Paris and Montpellier (Drs Cuisset and Touitou) and
those of the French specialized biochemical laboratory in Lyon
(Dr Acquaviva-Bourdain). The genomic DNA was extracted
from primary skin fibroblasts, white blood cells (ie, lympho-
cytes and leukocytes), or lymphoblasts from MKD patients.
The inclusion criteria were: age upon 16 years at diagnosis;
presence of 2 pathological mutations in the MK gene; or low
lymphocyte and/or fibroblast MK activity, and/or increased
MA in patients with genetically MKD family history and/or
typical recurrent febrile attacks (without individual molecular
diagnosis). The patients with insufficient collected data were
excluded. The data were recorded from the completed ques-
tionnaire sent with the enzymatic analysis request, and from the
contact with all referring physicians (e-mail and/or phone). The
authorizations from physicians and patients were requested. We
collected demographic data (gender, age at diagnosis, age at
Durel et alonset of disease, family history, vital status), clinical features
(length and recurrence of febrile crises, evolution of crises with
increasing age, triggering factors, organ involvement),
2 | www.md-journal.combiological evaluation (inflammatory markers, serum Ig concen-
trations, MK activity, MA, genetic features), histological results
if available, and tried treatments after diagnosis. The alternative
diagnoses evoked before MKD diagnosis was recorded. The
remission was defined as the absence of both clinical symptoms
and inflammatory biological syndrome.
RESULTS
Demographic Features
Twenty-seven patients were screened. Four patients were
excluded: diagnosis before 16 years in 1 patient, and insufficient
data in 3 patients. Twenty-three patients (14 women and 9 men)
were analyzed, including 1 asymptomatic patient. Some
patients have been previously described in case reports or
series.12,14,15
The demographic data were shown in Table 1. The mean
follow-up after diagnosis was 7 years (range 1–13). The mean
age at diagnosis was 40 years (range 16–79), with a mean age at
onset of symptoms of 9 years (range 0.2–77). A patient had a
late onset of manifestations at age of 77 years with a diagnosis
made 2 years later. The diagnosis was delayed with a median of
30.6 years after onset of symptoms. Ten patients (43.5%) had
familial histories of MKD. Thirteen patients (59.1%) had first
clinical features before 5 years, and all but 4 before 10 years
(81.8%). At time of diagnosis, 9 patients (40.9%) had a mean of
1 to 2 attacks monthly, and 11 (50%) had 1 monthly. Trigger-
ing factors were identified in 16 patients (72.7%), which were
infection (n¼ 12), vaccination (n¼ 9), and condition associated
with estrogen level variation as pregnancy in 3 patients and
menstrual period in one patient.
Most of the time, febrile attacks were triggered by viral
ear-nose-throat infections.
Fourteen patients (60.7%) had an alternative diagnosis
before diagnosis of MKD: 9 juvenile idiopathic arthritis, 3
rheumatoid purpura, and 2 acute articular rheumatisms.
Clinical Features
Table 2 showed the main clinical features. Considering
the symptomatic patients, febrile attacks were noticed in all
patients. The median duration of febrile attacks ranged from 3
to 7 days, never under 2 days or upon 10 days. The articular
symptoms affected 21 patients (95.5%), being most of time
Familial cases, n (%) 10 (43.5)
Death, n (%) 5 (21.7)arthralgia without synovitis (90.9%). One patient developed
severe destructive arthritis mimicking rheumatoid arthritis. A
tumoral syndrome occurred in 21 patients (95.5%). Nineteen
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.






Fever 22 (95.7) 100
Articular symptoms 21 (91.3) 95.5
Arthralgia 20 (87.0) 90.9
Arthritis 11 (47.8) 50.0
Tumoral syndrome 21 (91.3) 95.5




Gastrointestinal symptoms 20 (87.0) 90.9
Abdominal pain 19 (82.6) 86.4
Diarrhea 11 (47.8) 50.0
Vomiting 7 (30.4) 31.8
Skin lesions 19 (82.6) 86.4
Pharyngitis 14 (60.9) 63.6
Cough 13 (56.5) 59.1
Headache 8 (34.8) 36.4
Aphtous ulcers 7 (30.4) 31.8
Psychiatric symptoms 7 (30.4) 31.8
Ocular symptoms 5 (21.7) 22.7
Conjunctivitis 3 (13.0) 13.6
Uveitis 2 (8.7) 9.1
Optic neuritis 1 (4.3) 4.5
Medicine  Volume 95, Number 11, March 2016patients had lymphadenopathies (82.6%), among whom 16 had
cervical localization (84.2%). Hepatomegaly and/or spleno-
megaly affected 50% of patients. Twenty patients (90.9%)
presented with digestive manifestations that were abdominal
pain, diarrhea, or vomiting. One patient suffered from choles-
tasis and recurrent hyperammoniema episodes without other
enzymatic deficiencies. The skin lesions were found in
19 patients (86.4%) that were mainly maculopapular rash.
Nevertheless, urticarial lesions, and purpura were also
reported. One woman experienced chronic cutaneous purpura
persisting between attacks. Fourteen patients (63.6%) had
pharyngitis, 13 patients (59.1%) experienced cough, and 6
patients (27.3%) suffered from otitis. Headache, aphtous ulcers,
and ocular symptoms affected approximately one-third of
patients. Three patients (13.0%) had conjunctivitis, 2 patients
Renal manifestations 3 (13.0) 13.6(9.1%) uveitis, and 1 patient (4.5%) optic neuritis. One patient
had recurrent seizures related to MKD that began during adoles-
cence. Psychiatric features, especially depression, were notified
TABLE 3. Laboratory Results
Variable
Mevalonic aciduria (mmol/mol creatinine) (N <2)
Mevalonate kinase activity (%) (N¼ 2.5–7.8)
Serum Immunoglobulin D level (mg/L) (N¼ 7.7–132.1)
Serum Immunoglobulin A level, g/L (N¼ 0.8–2.7)
N: normal value.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in 7 patients (31.8%). One patient was described as a schizoid
personality. We identified 3 patients (13.6%) with renal involve-
ment: segmental and focal glomerulosclerosis, systemic AA
amyloidosis, and extracapillar glomerulonephritis. Two patients
(9.1%) had renal angiomyolipoma. No macrophage activation
syndrome was observed.
Laboratory Results
All patients had high elevated C-reactive protein (CRP)
during attacks (median 24.1mg/dL). All patients had micro-
biological analyses to exclude infectious diseases before con-
sidering inflammatory syndrome to be linked to MKD. Between
febrile attacks, most of them had normalization of the inflam-
mation markers, but 4 patients had low persistent biological
inflammation (CRP 1mg/dL). The biological results are
shown in Table 3. An elevated IgD concentration was
noted in 20 of the 21 tested patients (median 812mg/L; range
330–3750); 1 patient had normal IgD concentration. The IgD
dosage was high during febrile episode but also between febrile
attacks. We used the highest known concentration of IgD to
calculate the median and mean values of IgD values in our
series. The IgA concentration was elevated to a median level
of 7.6 g/L (range 3.8–16.9). The median IgG concentration
was in normal range, and the median IgM level was decreased.
The median MK activity was decreased to 0.1mkat/kg protein
(range 0–0.45). The median MA was elevated to 5.1mmol/mol
creatinine (range 1.7–28.2).
The MKD diagnosis was genetically confirmed in
21 patients (Table 4). Five patients were homozygous, and
16 were compound heterozygous. p.Val377Ile was the most
prevalent mutation with a frequency of 40.5% of all MKD
alleles, and was found in 14 of the 21 tested patients (66.7%).
The 2 most common mutations (p.Val377Ile and p.Ile268Thr)
accounted for 50% of mutations.
Nine patients experienced biopsies (lymphadenopathy,
skin, bone marrow) that showed nonspecific neutrophilic
inflammatory infiltrates.
Treatments
Various treatments were tried to treat and prevent attacks
(Table 5). Steroids were prescribed in 19 patients with partial to
good response. Nonsteroidal anti-inflammatory therapies were
used in 16 patients with an inconstant success. Colchicine (14
patients) aand statins (7 patients) were associated with limited
or no response. Besides, statins were often bad-tolerated. Inter-
leukin (IL)-1 receptor antagonists were used, with success, in 9
Mevalonate Kinase Deficiency in Adulthoodpatients. Anti-tumor necrosis factor (TNF)a drugs (infliximab,
adalimumab, etanercept) were used in 5 patients with partial
response. Apart from those drugs, other molecules were
Results
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Durel et aladministered with low or no success, and sometimes not
well-tolerated: intravenous immunoglobulins, methotrexate,
salazopyrine, hydroxychloroquine, leflunomide, azathioprine,
thalidomide, mycophenolate mofetil, cyclosporine, rituximab,
abatacept, tocilizumab, lenalidomide.
Follow-up
More than 65% of patients displayed a significant decrease
in severity and frequency of attacks with increasing age, and in
the absence of any immunomodulatory drug. Indeed, 12 patients
among the 18 questioned patients attested a decrease in the
number and the severity of the febrile attacks in adulthood. No
data were available for 4 patients because of lost of follow-up.
Only 7 patients (35%) achieved remission at the last follow-up
visit; 5 of them received IL-1 receptor antagonist.
One woman developed AA amyloidosis that had revealed
MKD, with renal and digestive localizations. She first devel-

42 Alleles analyzed.oped proteinuria, then end-stage chronic kidney disease that
required dialysis 7 years after MKD diagnosis. One patient had










Colchicine (n¼ 14) 0 (0)
Anti-IL1r (n¼ 9) 4 (44.4)
Statin (n¼ 7) 0 (0)
Anti-TNFa (n¼ 5) 0 (0)
IL¼ interleukin, TNF¼ tumor necrosis factor.
4 | www.md-journal.comFive patients (21.7%) died at a mean age of 56 years; 2
patients had septic shocks (one after digestive occlusion due to
amyloidal colic stenosis), 2 had solid neoplasms (respectively
liver and bladder tumor), and 1 suicide.
DISCUSSION
This multicenter study reveals that the clinical and genetic
spectrum of MKD diagnosed in adulthood does not furiously
differ from classical pediatric phenotype. This observational
study is, to our knowledge, the only series focusing on adult-
hood diagnosed MKD. Besides, it is the first to describe the
natural history of the disease. The diagnosis delay could be
linked to physician misunderstanding.
We confirm that MKD is a multisystemic disorder that
could be associated with renal angiomyolipoma, erosive arthri-
tis, crescentic glomerulonephritis, and neuropsychological dis-
orders.12,14 Moreover, recurrent febrile attacks could lead to a
severe complication, that is, AA amyloidosis as in 1 patient in
our series. HIDS typical clinical features consist of high-grade
fever episodes exceeding 408C last 3 to 7 days and recurring
every 4 to 6 weeks, sometimes triggered by vaccination,
infection, trauma, or stress.16 A triggering factor is noted in
16 patients in our cohort (72.7%). Explanation should be a
defective apoptosis of peripheral-blood lymphocytes leading to
severe inflammatory response regarding on minor triggering
factors.17 Pregnancy is suspected to trigger attacks in 3 patients
in our series, but no physiopathological explanation is known.
Reduced triggering events with increasing age may explain the
lowest frequency and severity of attacks in adults.
Even if most patients have usually their first febrile attacks
within the first year of life, the median age of diagnosis was 10
years with a median diagnosis delay of 9.9 years in the largest
published series.12 In our cohort, >50% of patients are 5 years’
old or younger at onset of symptoms with a median age at onset
of symptoms of 3 years, but a mean age of 9 years. The early
childhood onset of febrile attacks is a key point of diagnosis; the
criterion of onset before the age of 5 years is indeed a clinical
feature that should evoke MKD.18 The latest age at onset of
symptoms that we report could be explained by a memory bias.
Indeed, adult patients self-report their own symptoms that could
lead to imprecision. In pediatric studies, the histories of febrile
attacks are reported by parents with more precision. However, 3
patients clearly described the beginning of febrile attacks during
adolescence. In addition, this series confirms a significant
Medicine  Volume 95, Number 11, March 2016diagnosis delay linked to medical misunderstanding of a rare
disease. Moreover, frequent alternative diagnoses are retained







9 (47.4) 3 (15.8) 0 (0)
11 (68.8) 4 (25.0) 0 (0)
4 (28.6) 8 (57.1) 2 (14.3)
5 (55.6) 0 (0) 1 (11.1)
3 (42.9) 4 (57.1) 3 (42.9)
4 (80.0) 1 (20.0) 0 (0)
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.









Fever 100 100 100 1
Arthralgia 67 83.5 90.9 0.02
Lymphadenopathy 72 87.4 86.4 0.06
Abdominal pain 65 85.4 86.4 0.01
Skin lesions 67 68.9 86.4 0.17
Diarrhea 70 71.6 50.0 0.12
Arthritis 43 55.3 50.0 0.35
Hepatosplenomegaly 65y 54.0 50.0 0.37
Headache 17 63.3 36.4 <103
Vomiting 45 70.9 31.8 <103
Aphtous ulcers 43 48.5 31.8 0.28

Method: Comparisons between groups were performed by generalized Fisher exact test. When overall significant, the comparison 2 by 2 was
Medicine  Volume 95, Number 11, March 2016 Mevalonate Kinase Deficiency in Adulthoodseries is 28.8 years. All these data support that MKD remains a
diagnosis challenge, especially in adults.
As previously reported, arthralgia, lymphadenopathy, and
abdominal symptoms are the most common organ involvements
during attacks in our patients.12,14 Table 6 shows MKD clinical
features in the 2 largest previous series and in our cohort.12,14
Fever is constant. Arthralgia, abdominal pain, headache, and
vomiting are significantly different between the 3 studies, but
did not differ between our adulthood series, and the 2 previous
series that included pediatric and adult patients. Compared with
pediatric MKD, a latest diagnosis tends to lead to most common
arthralgia and skin lesions, whereas diarrhea, vomiting, aphtous
ulcers, and hepatosplenomegaly are less often reported (NS).
There is a similar proportion of lymphadenopathy, abdominal
pain, and arthritis. As already described, renal angiomyolipoma
is observed in 2 patients. This large renal tumor leads to
nephrectomy in one of our patients. The link between angio-
myolipoma and MKD is not well explained, but our data and
other cases series suggest that this association is not adventi-
tious.14 In 1 case, MKD is diagnosed in a patient presenting with
rapidly progressive crescentic glomerulonephritis; such
manifestation has already been reported in MKD course in
children.14,19,20 So, MKD should be evoked in patients present-
ing with crescentic glomerulonephritis without obvious diag-
noses (lupus nephritis, ANCA-associated vasculitis, or Good-
pasture disease) and a history of febrile attacks. Cholestasis
observed in 1 patient has been previously reported.21 Psychia-
tric manifestations are not uncommon, mainly depressive con-
ditions that could be related either toMKD clinical symptoms or
owing to patients’ health status12 For instance, a new case of
suicide occurred in 1 of our patients. Regarding neurological
features, recurrent seizures occur in 1 patient. This may under-
line the continuous spectrum between HIDS and MA; no
neurologic features are usually reported in HIDS.6,18 A chronic
vasculitic purpura is described in 1 patient. Significantly, this
purpura evolves individually without remission between
attacks. We report cough as a frequent symptom during attacks.
To our best knowledge, this is the first time that cough is
described as a clinical feature of MKD. A feverish cough may
performed.
ySplenomegaly only.mimic pulmonary infection and may delay diagnosis of MKD
attacks and the corticosteroid introduction. Nevertheless,
previous series suggested a susceptibility to bacterial infection
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in MKD.12,14,22 We report 2 deaths related to septic shock,
meaning a link between immunodeficiency and MKD.12,22,23
However, the use of steroids could also explain a part of the
infection susceptibility. Conversely to published data, we do not
find hypogammaglobulinemia in our cohort.14,24
The elevation of IgD has frequently helped guiding phys-
icians to diagnose MKD in our series. Nevertheless, 1 patient
exhibits normal IgD level what is concordant with precedent
publications.3,13,25,26 Even if elevated IgD level is also found in
other autoinflammatory diseases, strong elevation of IgD (>3
times the upper limit) is more specific for MKD. Our data
illustrate the diagnostic value of the IgD dosage in adults
compared with children (normal value in 4.3% in adults vs
22% in children).12,13,27–29 We observed persistent biological
inflammatory syndrome between attacks in 4 patients. Surpris-
ingly, the patient diagnosed with AA amyloidosis is not con-
cerned. All of these patients have persistent febrile attacks
despite anti-inflammatory drugs.
There is no obvious relation between phenotype and
genotype. As already reported, the p.Val377Ile mutation is
the most common mutation reported.14 All the mutations are
registered in an online registry called INFEVERS.30 The 2 most
prevalent mutations in our series are p.Val377Ile and
p.Ile268Thr that is concordant with previous pediatric series.12
Two mutations (p.Leu230Pro and p.Val310Leu) have not been
reported in children. Most of the others mutations represent only
1 allele in the cohort making difficult to conclude to any
association between genetic status and specific clinical features.
Furthermore, genotype-phenotype correlation studies in MKD
are contradictory.9,12,14,18,31 Studies promote the hypothesis
that there is no strict relationship between genotype and phe-
notype severity.9,14 p.Val377Ile is exclusively associated with
the mild HIDS phenotype, whereas other mutations are found in
both HIDS and MA, such as p.Ile268Thr.31 p.Val377Ile homo-
zygous patients are attempted to have a milder severity of MKD
or to be asymptomatic.10 In our series, the asymptomatic patient
is p.Val377Ile homozygous, like her symptomatic sister with a
mild activity of the disease. Nevertheless, one p.Val377Ile
homozygous patient in our cohort exhibits a more serious HIDS
phenotype. To explain the differences among the clinical
spectrum of MKD, modulating factors should exist to attenuate
the level of severity. Additional genetic studies should be
www.md-journal.com | 5
performed to identify such potential modifying factors that
could be mutations in introns, noncoding exons, squaring
sequences or promoters in MK gene, or in another modifying
gene. Some studies support the idea of a better correlation
between clinical features and residual MK activity that would
impact phenotype severity.3,9,31,32 MK activity is greatly
affected in MA (<0.5% of normal) rather than in HIDS with
an activity from 1.8% to 28%. In HIDS, most of the MK
mutations affect stability or folding of the encoded mutant
protein.3 In MA, mutations must have a more deleterious effect
on MK protein folding and/or may direct effect MK catalytic
properties.31 Besides, the residual activity of MK enzyme can
be manipulated by environmental conditions; temperature wor-
sens the folding defect.31,33 This must be clinically relevant in
febrile patients, and could explain why ear-nose-throat (ENT)
infection is a triggering factor of MKD attacks.
Considering treatments, most of our patients receive corti-
costeroids or nonsteroidal anti-inflammatory drugs. IL-1 receptor
antagonist is used with success in 9 patients. Two prospective
trials and others series confirm the effectiveness of anakinra in
MKD.14,34–37 Further data are requested to draw definitive con-
clusions. This suggests a crucial role of IL-1 and inflammasome in
the pathogenesis of MKD.34,38 Anakinra could be used daily or
during febrile attacks only. Furthermore, a continuous treatment
with anakinra decreases serum amyloid A level and could so
prevent amyloidosis.37 Anakinra would have greater effect than
anti-TNFa agents.35 Nevertheless, incomplete responses to ana-
kinra suggest the implication of others cytokines.39 Advances in
pathogenesis, that is, inflammasome activation, provide the basis
for the development of new therapies. Successful treatmentwould
prevent long-term severe complications.
Indeed, we report 2 infrequent but severe complications.
The first case, already published, is a severe erosive arthritis in a
young woman mimicking rheumatoid arthritis.15 There are
serious structural damages with narrowing of metacarpopha-
langeal joint spaces and carpitis. Anakinra allows inflammatory
joint pain resolution after failure of sulfasalazine, leflunomide,
and etanercept. The second complication is a new case of
systemic AA amyloidosis, revealing MKD. AA amyloidosis
is a frequent and severe complication in the autoinflammatory
diseases, but less common in HIDS (<3%).40,41 The usual
decrease of MKD attacks with increasing age could explain
the lowest risk of AA amyloidosis. Indeed, AA amyloidosis
complicates disorders with sustained acute-phase response and
persistent elevation of serum amyloid A protein level.42 Unfor-
tunately, we were not able to report the dosage of serum amyloid
A protein in our patients. To our knowledge, 5 previous cases of
AA amyloidosis in MKD have been published.43–46 All cases
have histories of febrile attacks since childhood, and are 7 to 29
years’ old. We report the sixth case. The patient first develops
nephrotic syndrome, then end-stage chronic kidney disease, and
is finally dialyzed at 69 years. Histories of recurrent febrile
attacks have led to MKD diagnosis at 70 years. She suffers from
febrile crises for 60 years before onset of an overt proteinuria.
She is compound heterozygous (p.Val377Ile - p.Ile268Thr)
sharing the same genetic status with another of the 5 patients.45
Despite lower frequency of AA amyloidosis in MKD, such a
condition could complicate long-term course of the disease.13,47
Early diagnosis and treatment of MKD are needed to prevent
development of the life-threatening systemic AA amyloidosis.
To conclude, this study has some limits related to its
Durel et alretrospective character leading to a potential lack of data,
and memory bias. We try to limit bias by contacting each
referring physicians; we collect a maximum of written
6 | www.md-journal.cominformation to ameliorate exhaustivity. Besides, we exclude
from analysis 3 patients because of insufficient data. All but 2
cases are genetically proven and systematically collect from
laboratories of interest. This is the first study interesting in
adulthood MKD and reporting about the spontaneous course of
the disease. MKD diagnosed in adulthood shares clinical and
genetic features with classical pediatric disease (see Table 6).
Interestingly, we report a good diagnostic value of the serum
IgD in adults. In cases of suspicion of autoinflammatory disease
in adults, we suggest to dose IgD to help physicians to diagnose
MKD. Despite the dramatic symptoms during febrile attacks
and alteration of quality of life, prognosis remains good. Despite
decrease of the severity and frequency of attacks with increasing
age, only one-third of patients achieve remission. Amyloidosis
AA is rare but could complicate long-term course of MKD.
Physicians must keep in mind the existence of yet undiagnosed
MKD in adults because diagnosis and initiation of a successful
treatment would prevent febrile attacks and their complications,
and improve quality of life.
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